背景尽管先前研究提示,对重症脓毒症患者使用白蛋白治疗有潜在优势,但其效果并未完全确认。方法在多中心、开放性试验中,我们在100个重症监护室中随机选取患者1 818例,分别使用20%白蛋白和晶体液(白蛋白组)或单独使用晶体液(晶体液组)。在白蛋白组中,血清白蛋白目标浓度至少为30 g/L,直到转出重症监护室或随机分组后28天。主要指标是28天任何原因病死率,次要指 Background Although previous studies have suggested the potential benefits of albumin therapy in patients with severe sepsis, the efficacy is not fully confirmed. Methods In a multicenter, open-label trial, we randomly selected 1818 patients from 100 intensive care units using either 20% albumin and lens fluid (albumin) or lens fluid alone (lens fluid). In the albumin group, serum albumin target concentration of at least 30 g / L until out of the intensive care unit or 28 days after randomization. The main indicator is the cause of death for any reason for 28 days, secondary refers to